Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAURA: AZD9291 vs Placebo in EGFRm+ Stage IB-IIIA NSCLC After Complete Resection
NCT02511106Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2015
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 25
01
Overview
A Phase 3 trial of osimertinib in non-small cell lung carcinoma (NSCLC), sponsored by AstraZeneca. Started Oct 2015; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT02511106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02511106.